| 000 | 01710 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515091426.0 | ||
| 264 | 0 | _c20071226 | |
| 008 | 200712s 0 0 ger d | ||
| 022 | _a0723-5003 | ||
| 024 | 7 |
_a10.1007/s00063-007-1102-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBramlage, Peter | |
| 245 | 0 | 0 |
_a[Albuminuria: an indicator of cardiovascular risk]. _h[electronic resource] |
| 260 |
_bMedizinische Klinik (Munich, Germany : 1983) _cOct 2007 |
||
| 300 |
_a833-43; quiz 844-5 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlbuminuria _xdiagnosis |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBenzimidazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers _xurine |
| 650 | 0 | 4 |
_aBiphenyl Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aCapillary Permeability _xdrug effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xdiagnosis |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrbesartan |
| 650 | 0 | 4 |
_aMembrane Potentials _xdrug effects |
| 650 | 0 | 4 |
_aProteinuria _xdiagnosis |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTetrazoles _xtherapeutic use |
| 700 | 1 | _aThoenes, Martin | |
| 700 | 1 | _aPaar, W Dieter | |
| 700 | 1 | _aBramlage, Carsten P | |
| 700 | 1 | _aSchmieder, Roland E | |
| 773 | 0 |
_tMedizinische Klinik (Munich, Germany : 1983) _gvol. 102 _gno. 10 _gp. 833-43; quiz 844-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00063-007-1102-8 _zAvailable from publisher's website |
| 999 |
_c17449816 _d17449816 |
||